China’s National Medical Products Administration (NMPA) has granted marketing approval to Shanghai HeartCare Medical Technology Co., Ltd (HKG: 6609) for its innovative intracranial aneurysm embolization assisted stent. This product is now cleared for use in clinical standard interventional surgical settings for intravascular embolization and blood flow reconstruction in patients diagnosed with intracranial aneurysms, with the aneurysm locations confirmed through angiography.
HeartCare Medtech’s Pioneering Stroke Treatment Solutions
Founded in 2016, HeartCare Medtech has been a pioneer in developing a comprehensive suite of solutions for stroke treatment and prevention within the realm of neurovascular intervention. The company’s product pipeline includes a range of instruments for nerve intervention treatments such as thrombectomy, aneurysm and stenosis interventions, interventional pathway instruments, and stroke prevention devices. HeartCare Medtech holds nearly 30 domestic medical device licenses, over 200 patents, and has two products under priority review status. The company’s marketing channels extend across all provinces in mainland China.- Flcube.com
